Publicacións en colaboración con investigadores/as de University of Paris-Sorbonne (49)

2024

  1. Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e206-e215

  2. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

  3. Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023

    Nature Medicine

  4. Pediatric Inferior Turbinate Hypertrophy: Diagnosis and Management. A YO-IFOS Consensus Statement

    Laryngoscope, Vol. 134, Núm. 3, pp. 1437-1444

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Adeno-associated virus 2 infection in children with non-A–E hepatitis

    Nature, Vol. 617, Núm. 7961, pp. 555-563

  3. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

    Alzheimer's Research and Therapy, Vol. 15, Núm. 1

  4. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses

    European heart journal. Quality of care & clinical outcomes, Vol. 9, Núm. 2, pp. 194-202

  5. Genomic investigations of unexplained acute hepatitis in children

    Nature, Vol. 617, Núm. 7961, pp. 564-573

  6. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe

    Clinical Infectious Diseases, Vol. 76, Núm. 9, pp. 1628-1635

2022

  1. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT

    Bone Marrow Transplantation, Vol. 57, Núm. 3, pp. 416-422

  2. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial

    European Heart Journal, Vol. 43, Núm. 29, pp. 2783-2797

  3. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978

  4. Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study

    Intensive Care Medicine, Vol. 48, Núm. 6, pp. 690-705

  5. Correction to: Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study (Intensive Care Medicine, (2022), 48, 6, (690-705), 10.1007/s00134-022-06705-1)

    Intensive Care Medicine

  6. Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (Bone Marrow Transplantation, (2022), 57, 3, (416-422), 10.1038/s41409-021-01553-x)

    Bone Marrow Transplantation

  7. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  8. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

    The Lancet, Vol. 399, Núm. 10326, pp. 741-755

  9. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

    New England Journal of Medicine, Vol. 386, Núm. 1, pp. 11-23

  10. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412